Tarka

Product manufactured by Abbvie Inc.

Application Nr Approved Date Route Status External Links
NDA020591 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Tarka Is Indicated For The Treatment Of Hypertension. This Fixed Combination Drug Is Not Indicated For The Initial Therapy Of Hypertension (see Dosage And Administration ). In Using Tarka, Consideration Should Be Given To The Fact That An Angiotensin Converting Enzyme Inhibitor, Captopril, Has Caused Agranulocytosis, Particularly In Patients With Renal Impairment Or Collagen Vascular Disease, And That Available Data Are Insufficient To Show That Trandolapril Does Not Have Similar Risk (see Warnings - Neutropenia/agranulocytosis ).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Comments